ENERGI-F703 not checked
Energenesis Biomedical Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
2 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.”In the company’s words, NCT05930210 on ClinicalTrials.gov
- Tested for
- Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus, Wound, Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa, Epidermolysis Bullosa Simplex, Dystrophic Epidermolysis Bullosa
- Main trialPhase 3
- “This Phase 3 study is a randomized, double-blind, vehicle-controlled, multiple-center, parallel study to evaluate efficacy and safety of ENERGI-F703 GEL compared with vehicle control in subjects with Wagner Grade 1 to Grade 2 diabetic foot ulcers. Baseline target ulcer size (\<16 cm2 vs ≥16 cm2 ) will be included as a stratification factor. Subjects will be randomized 1:1 to receive ENERGI-F703 GEL or vehicle control using an interactive web response system for randomization to automatically assign a unique subject randomization number. Total duration of the study will be up to 31 weeks…”In the company’s words, NCT05930210 on ClinicalTrials.gov
Other drugs for Diabetic Foot Ulcer
- BIOxHEALApplied Biologics, LLC · Phase 3
- Amniotic Tissue AllograftBardia Anvar · Phase 3
- Xianglei Tangzu GaoOneness Biotech Co., Ltd. · Phase 2/3
- Nu-3 gelLakewood-Amedex Inc · Phase 2
- Antimicrobial Peptide PL-5 Topical SprayJiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. · Phase 2
- BB-101Blue Blood Biotech Corp. · Phase 2
Coming up1
- 15 Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Dec 2025 | A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer | |
| Phase 2Recruiting | 15 Mar 2027 | A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa | |
| Phase 2Unknown | 15 Mar 2025 | A Study to Evaluate ENERGI-F703 GEL in Venous Leg Ulcer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026